| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
144,770,000 |
| Market
Cap: |
550.13(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.335 - $8.78 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Adaptive Biotechnologies is a commercial-stage company developing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Co.'s immune medicine platform applies its main technologies to read the genetic code of a patient's immune system. Co.'s clinical diagnostic product, clonoSEQ, is authorized by the Food and Drug Administration for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia and is also available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
181,388 |
181,647 |
370,810 |
539,321 |
| Total Sell Value |
$624,469 |
$625,539 |
$2,103,520 |
$3,574,731 |
| Total People Sold |
8 |
8 |
9 |
11 |
| Total Sell Transactions |
8 |
9 |
13 |
36 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Neupert Peter M |
Director |
– • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
14,775 |
22,968 |
|
- |
|
| Peterson Tycho |
Chief Financial Officer |
• – – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
118,203 |
492,891 |
|
- |
|
| Benzeno Sharon |
Chief Commercial Ofc Imm Med |
• – – |
2023-03-06 |
4 |
S |
$8.57 |
$100,689 |
D/D |
(11,749) |
223,826 |
|
15% |
|
| Benzeno Sharon |
Chief Commercial Ofc Imm Med |
• – – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
132,979 |
235,575 |
|
- |
|
| Robins Chad M |
CEO and Chairman |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
354,610 |
2,270,764 |
|
- |
|
| Hershberg Robert |
Director |
– • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
14,775 |
75,968 |
|
- |
|
| Robins Harlan S |
Chief Scientific Officer |
• – – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
354,610 |
666,570 |
|
- |
|
| Sood Nitin |
Chief Commercial Officer, MRD |
• – – |
2023-03-06 |
4 |
AS |
$8.57 |
$57,085 |
D/D |
(6,661) |
240,823 |
|
-15% |
|
| Sood Nitin |
Chief Commercial Officer, MRD |
• – – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
132,979 |
247,484 |
|
- |
|
| Trigg Leslie |
Director |
– • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
14,775 |
25,907 |
|
- |
|
| Hershberg Robert |
Director |
– • – |
2023-02-02 |
4 |
OE |
$0.45 |
$23,850 |
D/D |
53,000 |
61,193 |
|
- |
|
| Adams R Mark |
Chief Operating Officer |
• – – |
2023-01-10 |
4 |
AS |
$8.58 |
$18,275 |
D/D |
(2,130) |
113,518 |
|
-30% |
|
| Adams R Mark |
Chief Operating Officer |
• – – |
2023-01-09 |
4 |
AS |
$8.50 |
$8,458 |
D/D |
(995) |
115,648 |
|
-29% |
|
| Piskel Kyle |
Principal Accounting Officer |
• – – |
2022-11-16 |
4 |
S |
$8.87 |
$8,506 |
D/D |
(959) |
46,706 |
|
6% |
|
| Piskel Kyle |
Principal Accounting Officer |
• – – |
2022-11-16 |
4/A |
S |
$8.87 |
$2,723 |
D/D |
(307) |
47,358 |
|
- |
|
| Sood Nitin |
Chief Commercial Officer, MRD |
• – – |
2022-11-01 |
4 |
AS |
$8.00 |
$248,528 |
D/D |
(31,066) |
114,505 |
|
-2% |
|
| Adams R Mark |
Chief Operating Officer |
• – – |
2022-10-10 |
4 |
AS |
$7.13 |
$16,285 |
D/D |
(2,284) |
116,643 |
|
28% |
|
| Adams R Mark |
Chief Operating Officer |
• – – |
2022-10-07 |
4 |
AS |
$7.61 |
$6,400 |
D/D |
(841) |
118,927 |
|
23% |
|
| Sood Nitin |
Chief Commercial Officer, MRD |
• – – |
2022-08-05 |
4 |
S |
$10.98 |
$192,589 |
D/D |
(17,540) |
145,571 |
|
30% |
|
| Adams R Mark |
Chief Operating Officer |
• – – |
2022-07-08 |
4 |
AS |
$10.47 |
$24,081 |
D/D |
(2,300) |
119,768 |
|
-14% |
|
| Adams R Mark |
Chief Operating Officer |
• – – |
2022-07-07 |
4 |
AS |
$9.53 |
$7,862 |
D/D |
(825) |
122,068 |
|
-15% |
|
| Peterson Tycho |
Chief Financial Officer |
• – – |
2022-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
374,688 |
374,688 |
|
- |
|
| Adams R Mark |
Chief Operating Officer |
• – – |
2022-04-07 |
4 |
S |
$13.17 |
$10,944 |
D/D |
(831) |
122,893 |
|
15% |
|
| Robins Chad M |
CEO and Chairman |
• • – |
2022-03-09 |
4 |
AS |
$12.46 |
$184,595 |
D/D |
(14,815) |
1,916,154 |
|
-28% |
|
| Robins Chad M |
CEO and Chairman |
• • – |
2022-03-09 |
4 |
OE |
$6.32 |
$93,631 |
D/D |
14,815 |
1,930,969 |
|
- |
|
867 Records found
|
|
Page 3 of 35 |
|
|
0.30 (8.57%) 
